Generation Bio Co. is a leading Pharmaceuticals company based in the United States of America. With a high ESG score of 32.6, the company is committed to creating durable and redosable gene therapies for rare and untreated diseases. Generation Bio Co. specializes in liver and retina-related diseases, developing innovative platforms such as ctLNP delivery system for nucleic acids and iqDNA for highly selective therapeutic applications.